Management of chronic visceral pain

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig. Dis. Sci. 45(6), 1166–1171 (2000).
  Medline CASGoogle Scholar
• 2 Cervero F. Conference Proceedings, 5th World Congress on Pain: visceral pain. In: Pain Research and Clinical Management. Dubner R, Gebhart GF, Bond MR (Eds). Amsterdam, The Netherlands, 216–226 (1988).
  Google Scholar
• 3 Jänig W, Habler HJ. Visceral-autonomic integration. In: Visceral pain, Progress in Pain Research and Management. Gebhart GF (Ed.). IASP Press, WA, USA, 311–348 (1995).
  Google Scholar
• 4 Laird JM, Roza C, Cervero F. Effects of artificial calculosis on rat ureter motility: peripheral contribution to the pain of ureteric colic. Am. J. Physiol. 272(5 Pt 2), R1409–R1416 (1997).
  Medline CASGoogle Scholar
• 5 Gebhart GF. Visceral pain – peripheral sensitisation. Gut 47(Suppl. 4), iv54–iv55 (2000).
  MedlineGoogle Scholar
• 6 Olivar T, Laird JM. Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 79(1), 67–73 (1999).
  Medline CASGoogle Scholar
• 7 Lelic D, Olesen SS, Valeriani M, Drewes AM. Brain source connectivity reveals the visceral pain network. Neuroimage 60(1), 37–46 (2012).
  MedlineGoogle Scholar
• 8 IASP Taxonomy (2015). www.iasp-pain.org/Taxonomy.
  Google Scholar
• 9 Gebhart GF. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications IV. Visceral afferent contributions to the pathobiology of visceral pain. Am. J. Physiol. Gastrointest. Liver Physiol. 278(6), G834–G838 (2000).
  Medline CASGoogle Scholar
• 10 D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br. J. Anaesth. 101(1), 8–16 (2008).
  MedlineGoogle Scholar
• 11 Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 413(6852), 203–210 (2001).
  Medline CASGoogle Scholar
• 12 Anand P, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. 19(1), 29–46 (2007). •• A comprehensive and relevant discussion of the mechanisms that may underlie visceral hypersensitivity.
  Medline CASGoogle Scholar
• 13 Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 288(5472), 1765–1769 (2000).
  Medline CASGoogle Scholar
• 14 Al-Chaer ED, Lawand NB, Westlund KN, Willis WD. Visceral nociceptive input into the ventral posterolateral nucleus of the thalamus: a new function for the dorsal column pathway. J. Neurophysiol. 76(4), 2661–2674 (1996).
  Medline CASGoogle Scholar
• 15 Lottrup C, Olesen SS, Drewes AM. The pain system in oesophageal disorders: mechanisms, clinical characteristics, and treatment. Gastroenterol. Res. Pract. 2011, 910420 (2011).
  MedlineGoogle Scholar
• 16 Arendt-Nielsen L, Laursen RJ, Drewes AM. Referred pain as an indicator for neural plasticity. Prog. Brain Res. 129, 343–356 (2000).
  Medline CASGoogle Scholar
• 17 Frokjaer JB, Andersen SD, Gale J, Arendt-Nielsen L, Gregersen H, Drewes AM. An experimental study of viscero-visceral hyperalgesia using an ultrasound-based multimodal sensory testing approach. Pain 119(1–3), 191–200 (2005).
  MedlineGoogle Scholar
• 18 Olesen SS, Brock C, Krarup AL et al. Descending inhibitory pain modulation is impaired in patients with chronic pancreatitis. Clin. Gastroenterol. Hepatol. 8(8), 724–730 (2010).
  MedlineGoogle Scholar
• 19 Brinkert W, Dimcevski G, Arendt-Nielsen L, Drewes AM, Wilder-Smith OH. Dysmenorrhoea is associated with hypersensitivity in the sigmoid colon and rectum. Pain 132(Suppl. 1), S46–S51 (2007).
  MedlineGoogle Scholar
• 20 Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 152(3 Suppl.), S2–S15 (2011).
  MedlineGoogle Scholar
• 21 Cervero F. Visceral pain – central sensitisation. Gut 47(Suppl. 4), iv56–iv57 (2000).
  MedlineGoogle Scholar
• 22 Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 126(3), 683–692 (2004).
  Medline CASGoogle Scholar
• 23 Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 141(3), 191–209 (2009). •• A comprehensive review of the anatomical and molecular basis of gastrointestinal nociception.
  MedlineGoogle Scholar
• 24 Giamberardino MA, Costantini R, Affaitati G et al. Viscero-visceral hyperalgesia: characterization in different clinical models. Pain 151(2), 307–322 (2010). • An excellent study on viscerovisceral hyperalgesia providing evidence that several coexisting visceral pain conditions in the same patient increase each other's symptoms.
  MedlineGoogle Scholar
• 25 Giamberardino MA, Berkley KJ, Affaitati G et al. Influence of endometriosis on pain behaviors and muscle hyperalgesia induced by a ureteral calculosis in female rats. Pain 95(3), 247–257 (2002).
  MedlineGoogle Scholar
• 26 Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: specificity, recruitment and plasticity. Brain Res. Rev. 60(1), 214–225 (2009).
  Medline CASGoogle Scholar
• 27 Fields H. State-dependent opioid control of pain. Nat. Rev. Neurosci. 5(7), 565–575 (2004).
  Medline CASGoogle Scholar
• 28 Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res. Brain Res. Rev. 46(3), 295–309 (2004).
  MedlineGoogle Scholar
• 29 Gebhart GF. Descending modulation of pain. Neurosci. Biobehav. Rev. 27(8), 729–737 (2004).
  Medline CASGoogle Scholar
• 30 Greenwood-Van Meerveld B, Prusator DK, Johnson AC. Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 308(11), G885–G903 (2015).
  MedlineGoogle Scholar
• 31 Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99(1–2), 49–59 (2002).
  MedlineGoogle Scholar
• 32 Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 288(5472), 1769–1772 (2000).
  Medline CASGoogle Scholar
• 33 Shankland WE. Factors that affect pain behavior. Cranio 29(2), 144–154 (2011).
  MedlineGoogle Scholar
• 34 Drewes AM, Gregersen H. Multimodal pain stimulation of the gastrointestinal tract. World J. Gastroenterol. 12(16), 2477–2486 (2006).
  MedlineGoogle Scholar
• 35 Olesen AE, Andresen T, Staahl C, Drewes AM. Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs. Pharmacol. Rev. 64(3), 722–779 (2012).
  Medline CASGoogle Scholar
• 36 Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr. Opin. Investig Drugs 8(1), 41–53 (2007).
  Medline CASGoogle Scholar
• 37 Olesen AE, Brock C, Sverrisdottir E, Larsen IM, Drewes AM. Sensitivity of quantitative sensory models to morphine analgesia in humans. J. Pain Res. 7, 717–726 (2014).
  MedlineGoogle Scholar
• 38 Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122(4), 1140–1156 (2002).
  MedlineGoogle Scholar
• 39 Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274(23), 1870–1873 (1995).
  Medline CASGoogle Scholar
• 40 Holdgate A, Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 328(7453), 1401 (2004).
  MedlineGoogle Scholar
• 41 Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst. Rev. (7), CD001751 (2015).
  MedlineGoogle Scholar
• 42 Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst. Rev. (2), CD004753 (2009).
  MedlineGoogle Scholar
• 43 Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. (3), CD009590 (2014).
  MedlineGoogle Scholar
• 44 Nalamachu S. An overview of pain management: the clinical efficacy and value of treatment. Am. J. Manag. Care 19(14 Suppl.), s261–s266 (2013).
  MedlineGoogle Scholar
• 45 Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 283(13), 1710–1714 (2000).
  Medline CASGoogle Scholar
• 46 Staahl C, Dimcevski G, Andersen SD et al. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand. J. Gastroenterol. 42(3), 383–390 (2007).
  Medline CASGoogle Scholar
• 47 Wilder-Smith CH, Hill L, Osler W, O'Keefe S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig. Dis. Sci. 44(6), 1107–1116 (1999).
  Medline CASGoogle Scholar
• 48 Lopopolo M, Affaitati G, Fabrizio A et al. Effects of tramadol on viscero-visceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis. Fundam. Clin. Pharmacol. 28(3), 331–341 (2014).
  Medline CASGoogle Scholar
• 49 Warshaw AL, Banks PA, Fernandez-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology 115(3), 765–776 (1998).
  Medline CASGoogle Scholar
• 50 Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 20(2), 237–246 (2004).
  Medline CASGoogle Scholar
• 51 Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116(1), 38–45 (1999).
  Medline CASGoogle Scholar
• 52 Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 101(1–2), 89–95 (2003).
  Medline CASGoogle Scholar
• 53 Mercadante S, Tirelli W, David F et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin. J. Pain 26(9), 794–797 (2010).
  MedlineGoogle Scholar
• 54 Drewes AM, Jensen RD, Nielsen LM et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br. J. Clin. Pharmacol. 75(1), 60–78 (2013).
  Medline CASGoogle Scholar
• 55 Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63(7), 649–671 (2003).
  Medline CASGoogle Scholar
• 56 Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol. Motil. 16(Suppl. 2), 17–28 (2004).
  MedlineGoogle Scholar
• 57 Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 72(14), 1847–1865 (2012).
  Medline CASGoogle Scholar
• 58 Poulsen JL, Olesen SS, Malver LP, Frokjaer JB, Drewes AM. Pain and chronic pancreatitis: a complex interplay of multiple mechanisms. World J. Gastroenterol. 19(42), 7282–7291 (2013).
  MedlineGoogle Scholar
• 59 Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin. Exp. Gastroenterol. 7, 345–358 (2014).
  Medline CASGoogle Scholar
• 60 Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. Am. J. Gastroenterol. 2(1), 22–30 (2014).
  CASGoogle Scholar
• 61 Farmer AD, Ferdinand E, Aziz Q. Opioids and the gastrointestinal tract – a case of narcotic bowel syndrome and literature review. J. Neurogastroenterol Motil. 19(1), 94–98 (2013).
  MedlineGoogle Scholar
• 62 Bouwense SA, de Vries M, Schreuder LT et al. Systematic mechanism-orientated approach to chronic pancreatitis pain. World J. Gastroenterol. 21(1), 47–59 (2015).
  MedlineGoogle Scholar
• 63 Chen L, Mao J. Update on neuropathic pain treatment: ion channel blockers and gabapentinoids. Curr. Pain Headache Rep. doi: 10.1007/s11916-013-0359-2 (2013) (Epub ahead of print).
  Google Scholar
• 64 Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 22(10), 981–988 (2005).
  Medline CASGoogle Scholar
• 65 Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56(9), 1218–1225 (2007). • An interesting study showing that pregabalin exhibited several potentially important physiological effects on both rectal sensation and compliance.
  Medline CASGoogle Scholar
• 66 Olesen SS, Graversen C, Bouwense SA, van Goor H, Wilder-Smith OH, Drewes AM. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS ONE 8(3), e57963 (2013).
  Medline CASGoogle Scholar
• 67 Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 141(2), 536–543 (2011). • A study of interest as it provides evidence that the adjuvant administration of pregabalin for the treatment of pain in patients with chronic pancreatitis is superior to placebo.
  Medline CASGoogle Scholar
• 68 Tornblom H, Drossman DA. Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol. Motil. 27(4), 455–467 (2015). •• An excellent review providing an overview of centrally targeted pharmacotherapy for the treatment of chronic functional visceral pain.
  Medline CASGoogle Scholar
• 69 Ford AC, Quigley EM, Lacy BE et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 109(9), 1350–1365; quiz 1366 (2014).
  Medline CASGoogle Scholar
• 70 Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm. Bowel Dis. 20(12), 2433–2449 (2014).
  MedlineGoogle Scholar
• 71 Bell RF. Ketamine for chronic non-cancer pain. Pain 141(3), 210–214 (2009).
  Medline CASGoogle Scholar
• 72 Bouwense SA, Buscher HC, van Goor H, Wilder-Smith OH. S-ketamine modulates hyperalgesia in patients with chronic pancreatitis pain. Reg. Anesth. Pain Med. 36(3), 303–307 (2011).
  Medline CASGoogle Scholar
• 73 Juel J, Olesen SS, Olesen AE et al. Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial). BMJ Open 5(3), e007087 (2015).
  MedlineGoogle Scholar
• 74 Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 74(6), 619–626 (2014).
  Medline CASGoogle Scholar
• 75 Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J. Urol. 185(5), 1716–1721 (2011).
  Medline CASGoogle Scholar
• 76 Zhu Y, Colak T, Shenoy M et al. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology 141(1), 370–377 (2011).
  Medline CASGoogle Scholar
• 77 Lee Y, Hong S, Cui M, Sharma PK, Lee J, Choi S. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011–2014). Expert Opin. Ther. Pat. 25(3), 291–318 (2015).
  Medline CASGoogle Scholar
• 78 Lapointe TK, Basso L, Iftinca MC et al. TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 309(2), G87–G99 (2015).
  Medline CASGoogle Scholar
• 79 Altomare A, Guarino MP, Emerenziani S et al. Gastrointestinal sensitivity and gastroesophageal reflux disease. Ann. NY Acad. Sci. 1300, 80–95 (2013).
  Medline CASGoogle Scholar
• 80 Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57(7), 923–929 (2008).
  Medline CASGoogle Scholar
• 81 Chey WD, Lembo AJ, Lavins BJ et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am. J. Gastroenterol. 107(11), 1702–1712 (2012).
  Medline CASGoogle Scholar
• 82 Busby RW, Bryant AP, Bartolini WP et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649(1–3), 328–335 (2010).
  Medline CASGoogle Scholar
• 83 Castro J, Harrington AM, Hughes PA et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate. Gastroenterology 145(6), 1334–1346.e1–11 (2013).
  Medline CASGoogle Scholar
• 84 Dumitrascu DL, Chira A, Bataga S et al. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J. Gastrointestin Liver Dis. 23(4), 431–435 (2014).
  MedlineGoogle Scholar
• 85 Dunphy RC, Verne GN. Drug treatment options for irritable bowel syndrome: managing for success. Drugs Aging 18(3), 201–211 (2001).
  Medline CASGoogle Scholar
• 86 Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr. Gastroenterol. Rep. doi:10.1007/s11894-015-0429-1 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 87 Ruffle JK, Bajgoric S, Samra K, Chandrapalan S, Aziz Q, Farmer AD. Cannabinoid hyperemesis syndrome: an important differential diagnosis of persistent unexplained vomiting. Eur. J. Gastroenterol. Hepatol. 27(12), 1403–1408 (2015).
  Medline CASGoogle Scholar
• 88 Vickers AJ, Cronin AM, Maschino AC et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch. Intern. Med. 172(19), 1444–1453 (2012).
  MedlineGoogle Scholar
• 89 Witt C, Brinkhaus B, Jena S et al. Acupuncture in patients with osteoarthritis of the knee: a randomised trial. Lancet 366(9480), 136–143 (2005).
  Medline CASGoogle Scholar
• 90 Ng SS, Leung WW, Mak TW et al. Electroacupuncture reduces duration of postoperative ileus after laparoscopic surgery for colorectal cancer. Gastroenterology 144(2), 307–313.e1 (2013).
  MedlineGoogle Scholar
• 91 Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651), 999–1003 (2008).
  MedlineGoogle Scholar
• 92 Juel J, Liguori S, Liguori A et al. A new method for sham-controlled acupuncture in experimental visceral pain – a randomized, single-blinded study. Pain Pract. doi:10.1111/papr.12309 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 93 Moisset X, de Andrade DC, Bouhassira D. From pulses to pain relief: an update on the mechanisms of rTMS-induced analgesic effects. Eur. J. Pain doi:10.1002/ejp.811 (2015) (Epub ahead of print).
  Google Scholar
• 94 Melchior C, Gourcerol G, Chastan N et al. Effect of transcranial magnetic stimulation on rectal sensitivity in irritable bowel syndrome: a randomized, placebo-controlled pilot study. Colorectal Dis. 16(3), O104–O111 (2014).
  Medline CASGoogle Scholar
• 95 Algladi T, Harris M, Whorwell PJ, Paine P, Hamdy S. Modulation of human visceral sensitivity by noninvasive magnetoelectrical neural stimulation in health and irritable bowel syndrome. Pain 156(7), 1348–1356 (2015).
  MedlineGoogle Scholar
• 96 Fregni F, Potvin K, Dasilva D et al. Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain. Eur. J. Pain 15(1), 53–60 (2011).
  MedlineGoogle Scholar
• 97 Napadow V, Edwards RR, Cahalan CM et al. Evoked pain analgesia in chronic pelvic pain patients using respiratory-gated auricular vagal afferent nerve stimulation. Pain Med. 13(6), 777–789 (2012).
  MedlineGoogle Scholar
• 98 Frøkjær JB, Bergmann S, Brock C et al. Modulation of vagal tone enhances gastro-duodenal motility and reduces somatic pain sensitivity. Neurogastroenterol. Motil. (2015) (In Press).
  MedlineGoogle Scholar
• 99 Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 34(2), 281–303 (2005).
  MedlineGoogle Scholar
• 100 Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst. Rev. (1), CD006442 (2009).
  MedlineGoogle Scholar
• 101 Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin. Gastroenterol. Hepatol. 6(8), 899–906 (2008).
  MedlineGoogle Scholar
• 102 Mathew P, Bhatia SJ. Pathogenesis and management of irritable bowel syndrome. Trop. Gastroenterol. 30(1), 19–25 (2009).
  MedlineGoogle Scholar
• 103 Altayar O, Sharma V, Prokop LJ, Sood A, Murad MH. Psychological therapies in patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Gastroenterol. Res. Pract. 2015, 549308 (2015). •• A review of considerable interest as it provides evidence that psychological therapies may improve the quality of life and symptom severity in irritable bowel syndrome.
  MedlineGoogle Scholar
• 104 Miller V, Whorwell PJ. Hypnotherapy for functional gastrointestinal disorders: a review. Int. J. Clin. Exp. Hypn. 57(3), 279–292 (2009).
  MedlineGoogle Scholar
• 105 Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment. Pharmacol. Ther. 41(9), 844–855 (2015).
  Medline CASGoogle Scholar
• 106 Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome – the effect of hypnotherapy. Aliment. Pharmacol. Ther. 10(1), 91–95 (1996).
  Medline CASGoogle Scholar
• 107 Prior A, Colgan SM, Whorwell PJ. Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut 31(8), 896–898 (1990).
  Medline CASGoogle Scholar
• 108 Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (4), CD005110 (2007).
  MedlineGoogle Scholar
• 109 Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 2(8414), 1232–1234 (1984).
  Medline CASGoogle Scholar
• 110 Wilson S, Maddison T, Roberts L, Greenfield S, Singh S. Birmingham IBS Research Group. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment. Pharmacol. Ther. 24(5), 769–780 (2006).
  Medline CASGoogle Scholar
• 111 Lovdahl J, Ringstrom G, Agerforz P, Tornblom H, Simren M. Nurse-administered, gut-directed hypnotherapy in IBS: efficacy and factors predicting a positive response. Am. J. Clin. Hypn. 58(1), 100–114 (2015).
  MedlineGoogle Scholar
• 112 Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am. J. Gastroenterol. 105(8), 1788, 1789–1794; quiz 1795 (2010).
  MedlineGoogle Scholar
• 113 Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352(13), 1324–1334 (2005).
  Medline CASGoogle Scholar